Independent
Tenure on this board
4.6 yrs
Meeting calendar
FULC · Annual meeting · Wednesday, June 24, 2026
Fulcrum Therapeutics Inc
3 nominees · 3 ballot items.
Election of three Class I directors; a non-binding advisory vote to approve named executive officer compensation (say-on-pay); ratification of Ernst & Young LLP as independent auditor for 2026; and transaction of any other business that may properly come before the Annual Meeting.
Market cap
$251M
1Y TSR
-51.1%
Board grade
C-
Record date
Apr 27, 2026
Filing
DEF 14A
Meeting concluded · Jun 24, 2026
Follow how the vote landed and what changed on Fulcrum Therapeutics Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot3
- 1
Election of three Class I directors
ManagementBoard: FORElect three Class I directors — Sonja Banks, Alan Ezekowitz, and Colin Hill — each for a three-year term expiring at the 2029 annual meeting.
- 2
Non-binding advisory vote on the compensation of our named executive officers
ManagementBoard: FORA non-binding advisory 'say-on-pay' vote to approve the compensation of the company's named executive officers as disclosed in the proxy statement.
More detail
We are providing our stockholders the opportunity to vote to approve, on a non-binding, advisory basis, the compensation of our named executive officers as disclosed in this proxy statement in accordance with the SEC’s rules. This proposal, which is commonly referred to as “say-on-pay,” is required by the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, which added Section 14A to the Exchange Act. Our executive compensation programs are designed to attract, motivate, and retain our executive officers. The programs contain elements of cash and equity-based compensation and are designed to align the interests of our executives with those of our stockholders. The vote is advisory and not binding, but the compensation committee and board will consider the outcome when making future compensation decisions. The board recommends a "FOR" vote, citing the design of the programs to reward achievement of near- and long-term goals, alignment with stockholders and avoidance of excessive risk-taking.
- 3
Ratification of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026
ManagementBoard: FORRatify the appointment of Ernst & Young LLP as Fulcrum's independent registered public accounting firm for fiscal year 2026.
Director elections
Nominees on the ballot3
Independent
Tenure on this board
9.6 yrs
Also a director at
Organon & Co (OGN)Septerna Inc (SEPN)
Independent
Tenure on this board
2.1 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | SUVRETTA CAPITAL MANAGEMENT, LLC | 9.8% | 6,561,111 | $50M |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 9.1% | 6,053,960 | $46M |
| 3 | TCG Crossover Management, LLC | 7.9% | 5,250,000 | $40M |
| 4 | BRAIDWELL LP | 4.7% | 3,134,922 | $24M |
| 5 | Nantahala Capital Management, LLC | 4.6% | 3,050,040 | $23M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 4.0% | 2,692,948 | $21M |
| 7 | BlackRock, Inc. | 3.8% | 2,564,122 | $20M |
| 8 | Siren, L.L.C. | 3.5% | 2,350,000 | $18M |
| 9 | First Turn Management, LLC | 3.4% | 2,256,109 | $17M |
| 10 | Aberdeen Group plc | 3.3% | 2,211,953 | $17M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Fulcrum Therapeutics Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Indaptus Therapeutics IncINDP
Annual meeting·Aug 10, 2026·$300M
Simulations Plus IncSLP
Special meeting·Aug 27, 2026·$369M
Seer IncSEER
Annual meeting·Jul 28, 2026·$114M
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$725M
Anaptysbio IncANAB
Annual meeting·Aug 11, 2026·$1.5B
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.7B
Reference
Frequently asked questions
- When is the Fulcrum Therapeutics Inc 2026 annual meeting?
- Fulcrum Therapeutics Inc (FULC) holds its 2026 annual shareholder meeting on Wednesday, June 24, 2026.
- What is the record date for the Fulcrum Therapeutics Inc 2026 meeting?
- The record date for the Fulcrum Therapeutics Inc 2026 meeting is Monday, April 27, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Fulcrum Therapeutics Inc's 2026 meeting?
- The board is presenting 3 director nominees at the Fulcrum Therapeutics Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Fulcrum Therapeutics Inc 2026 meeting?
- Shareholders will vote on 3 proposals at the Fulcrum Therapeutics Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.